Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P008 - Correlation Between Genetic Mutation State and Cancer-Associated Thrombosis in Advanced Cancer Patients (ID 33)
00:00 - 00:00 | Author(s): Z. Wang
To investigate the correlation between genetic mutation state and cancer-associated thrombosis in advanced cancer patients.
133 cases of advanced cancer patients were divided into mutation group and non-mutation group according to their genetic states. Venous Doppler ultrasound examination was performed to determine the incidence of thrombosis. Incidence of thrombosis was compared between 2 groups. Genetic mutation rate was calculated in thrombosis patients. Risk factors for thrombosis were analyzed in 2 groups. Sensitivity and specificity were compared using Khorana risk assessment model. Low-risk subgroups/middle-risk subgroups/high-risk subgroups were determined by Khorana risk assessment model in mutation/non-mutation group. Incidence of thrombosis were compared between corresponding subgroups (low-risk to low-risk, middle-risk to middle-risk, high-risk to high-risk).
1. Genetic mutation rate was 75.2% in all patients. Thrombosis rate was 13.53% in all patients. Genetic mutation rate in thrombosis patients was 88.89%. 2. Thrombosis rates in mutation/non-mutation group were 16.0% and 6.1%, respectively (P=0.2490). 3. The thrombosis rates in EGFR?ALK?TP53?Her-2?KRAS?PIK3CA?T790M gene mutation were 27.8%?5.6%?33.3%?5.6%?11.1%?0?5.6%, respectively (P=0.248,0.873,0.804,1.000,0.959,0.469,1.000). 4. Sensitivity and specificity in mutation group were 16.8% and 60.0% in Khorana risk assessment model. In non-mutation group those were 6.9% and 100.0%, respectively. AUC for 2 groups ROC were 0.571 and 0419, respectively (P>0.05). 5. Thrombosis rates for each corresponding subgroups were 33.3% vs 0% (mutation low-risk subgroup vs non-mutation low-risk subgroup), 10.7% vs 7.1% (mutation middle-risk subgroup vs non-mutation middle-risk subgroup) and 57.1% vs 0% (mutation high-risk subgroup vs non-mutation high-risk subgroup). P values were 0.497, 0.940, 1, separately.
There is no correlation between genetic mutation state and cancer-associated thrombosis in advanced cancer patients.